Table 6.
Comparisons of effect of untreated hypertension, treatment with anti-hypertensive medication (An), late-life hypertensive (HTN2), and normotensive (NT) status with Alzheimer’s disease incidence, for different FOXO3 rs2802292 genotypes
| Genotype | HTN2 group | Reference group | HR1 (95% CI) | p |
| TG/GG | HTN2 (n = 219) | NT (n = 570) | 0.59 (0.39–0.88) | 0.0099 |
| HTN2 (An) (n = 470) | NT (n = 570) | 0.72 (0.54–0.97) | 0.030 | |
| HTN2 (An) (n = 470) | HTN2 (n = 219) | 1.22 (0.80–1.86) | 0.34 | |
| TT | HTN2 (n = 204) | NT (n = 667) | 1.11 (0.75–1.63) | 0.60 |
| HTN2 (An) (n = 558) | NT (n = 667) | 1.15 (0.87–1.51) | 0.33 | |
| HTN2 (An) (n = 558) | HTN2 (n = 204) | 1.04 (0.70–1.54) | 0.86 |
1HR and (95% CI) was computed using the least square means estimated from the multivariate full Cox models for the HTN2 group and FOXO3 rs2802292 genotype. HRs were compared between HTN2 groups within each genotype (TT, and TG/GG). NT, SBP/DBP <160/95 mmHg; HTN2, untreated hypertension, SBP/DBP ≥160/95 mmHg and not taking anti-hypertensive medication; HTN2 (An), hypertensive subjects who reported taking anti-hypertensive medication.